Exploring the Interplay of Glioblastoma Angiogenesis, ROS, and Tumor Microenvironment: Advancements in Combination Therapy and Bioinformatics Approaches

Dear Colleagues,

Glioblastoma (GBM) is an aggressive brain tumor with significant angiogenesis, triggered by hypoxia-inducible factors (HIFs) and aggravated by reactive oxygen species (ROS). The tumor microenvironment (TME), which comprises immune cells and stromal components, is critical in therapeutic resistance. Conventional treatments such as radiation (RT) frequently fail due to the adaptive processes of the TME. Autophagy and apoptosis are critical cellular mechanisms that contribute to this resistance. Recent advances in cancer immunotherapy and combination medicines have provided promising alternatives. In silico and network pharmacology techniques, along with bioinformatics, provide tools for identifying novel therapeutic targets and optimizing treatment options. This Special Issue will address these pathways in order to create novel treatment modalities that improve GBM patient outcomes by using a combination of therapeutic techniques and precision medicine. We welcome the submission of review and original research articles that explore the intricate relationship between glioblastoma angiogenesis, ROS, and the tumor microenvironment, focusing on recent advancements in combination therapies and bioinformatic approaches.

Dr. Md Ataur Rahman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.